- Home
- VTRS
VTRS
Viatris Inc.
as 09-06-2024 4:00pm EST
Viatris was formed in November 2020 through the combination of Upjohn, a wholly owned subsidiary of Pfizer that specialized in off-patent drugs, and Mylan, a global pharmaceutical manufacturer that focused on generic and specialty drugs. By joining forces, Viatris became one of the largest generic drug manufacturers in the world, servicing over 165 countries. Generics (commoditized and complex) and biosimilars make up roughly 40% of Viatris' total sales. Remaining 60% of sales is derived from its portfolio of legacy products which includes Lipitor, Norvasc, Lyrica, and Viagra. While it covers more than 10 major therapeutic areas, Viatris has identified dermatology, ophthalmology, and gastroenterology as its three key areas of focus for future innovations.
| Founded: | 1961 | Country: | United States |
| Employees: | N/A | City: | CANONSBURG |
| Market Cap: | 12.9B | IPO Year: | N/A |
| Target Price: | $12.33 | AVG Volume (30 days): | 6.9M |
| Analyst Decision: | Hold | Number of Analysts: | 3 |
| Dividend Yield: | Dividend Payout Frequency: | Quarterly | |
| EPS: | -0.54 | EPS Growth: | N/A |
| 52 Week Low/High: | $8.74 - $13.62 | Next Earning Date: | 08-08-2024 |
| Revenue: | $15,239,200,000 | Revenue Growth: | -2.32% |
| Revenue Growth (this year): | -2.07% | Revenue Growth (next year): | -1.43% |
Stock Insider Trading Activity of Viatris Inc. (VTRS)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Malik Rajiv | VTRS | Director | Aug 28 '24 | Sell | $11.95 | 100,000 | $1,195,075.00 | 110,319 | |
| Malik Rajiv | VTRS | Director | Aug 21 '24 | Sell | $11.74 | 300,000 | $3,522,990.00 | 110,319 | |
| Malik Rajiv | VTRS | Director | Jun 13 '24 | Sell | $10.35 | 349,960 | $3,591,023.87 | 110,319 |
Latest Viatris Inc. News
VTRS Breaking Stock News: Dive into VTRS Ticker-Specific Updates for Smart Investing
ACCESSWIRE
3 days ago
Viatris 2023 Sustainability Report: Continued Innovation for Infectious Disease
MT Newswires
4 days ago
Viatris Launches Cash Tender Offers for Senior Notes
PR Newswire
4 days ago
Viatris Announces Cash Tender Offers for Certain Outstanding Notes
Argus Research
4 days ago
Analyst Report: Viatris Inc
Argus Research
4 days ago
Market Update: CRM, HAS, VTRS, TRGP
MT Newswires
5 days ago
Viatris Insider Sold Shares Worth $1,195,075, According to a Recent SEC Filing
Pharmaceutical Technology
6 days ago
ESC 2024: Single-pill hypertension combo delivers positive results
PR Newswire
16 days ago
Viatris Presents Late Breaking Abstract on Cenerimod at the 26th Asia-Pacific League of Associations for Rheumatology Annual Congress
Compare VTRS vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "VTRS Viatris Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.